Get the Stockscreener App
4.715
3.63%
0.165
Acurx Pharmaceuticals Inc stock is traded at $4.715, with a volume of 47,801.
It is up +3.63% in the last 24 hours and down -50.89% over the past month.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
See More
Previous Close:
$4.55
Open:
$4.55
24h Volume:
47,801
Relative Volume:
0.15
Market Cap:
$7.47M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-4.10
EPS:
-1.15
Net Cash Flow:
$-9.80M
1W Performance:
-7.73%
1M Performance:
-50.89%
6M Performance:
-69.88%
1Y Performance:
-89.79%
1-Day Range:
$4.4201
$4.75
1-Week Range:
$4.40
$5.285
52-Week Range:
$3.80
$47.60
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
4.715 | 8.16M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
What technical models suggest about Acurx Pharmaceuticals Inc.’s comebackTrade Signal Summary & Entry Point Strategy Guides - Newser
Strategies to average down on Acurx Pharmaceuticals Inc.Portfolio Performance Summary & Community Trade Idea Sharing - Newser
Acurx signals ongoing cost controls and new trial funding avenues while advancing ibezapolstat clinical program - MSN
Technical Models Detect Momentum Build in Acurx Pharmaceuticals Inc.Market Movement Recap & Real-Time Buy Signal Alerts - thegnnews.com
Technical analysis overview for Acurx Pharmaceuticals Inc. stockSell Signal & Verified Short-Term Trading Plans - Newser
Statistical indicators supporting Acurx Pharmaceuticals Inc.’s strength2025 Market Overview & Daily Price Action Insights - Newser
Published on: 2025-08-20 00:25:12 - Newser
What does recent volatility data suggest for Acurx Pharmaceuticals Inc.Earnings Recap Summary & Growth Focused Investment Plans - Newser
Will Acurx Pharmaceuticals Inc. benefit from macro trendsRate Cut & AI Optimized Trading Strategy Guides - Newser
Acurx Pharmaceuticals Inc. stock momentum explained2025 Macro Impact & Daily Entry Point Trade Alerts - Newser
Will Acurx Pharmaceuticals Inc. continue its uptrendMarket Trend Report & Stock Portfolio Risk Control - Newser
What’s the recovery path for long term holders of Acurx Pharmaceuticals Inc.Portfolio Risk Summary & Entry and Exit Point Strategies - Newser
Will a bounce in Acurx Pharmaceuticals Inc. offer an exitWeekly Gains Report & Community Trade Idea Sharing - Newser
Can volume confirm reversal in Acurx Pharmaceuticals Inc.Trend Reversal & High Accuracy Buy Signal Tips - Newser
Key metrics from Acurx Pharmaceuticals Inc.’s quarterly dataJuly 2025 Weekly Recap & Fast Momentum Entry Tips - Newser
Signal strength of Acurx Pharmaceuticals Inc. stock in tech scannersJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - Newser
How high can Acurx Pharmaceuticals Inc. stock goJuly 2025 Decliners & Breakout Confirmation Alerts - Newser
Real time pattern detection on Acurx Pharmaceuticals Inc. stockMarket Movers & AI Powered Trade Plan Recommendations - Newser
Why Acurx Pharmaceuticals Inc. stock attracts strong analyst attention2025 Major Catalysts & Free Growth Oriented Trading Recommendations - Newser
Published on: 2025-08-19 06:44:47 - Newser
Chart based exit strategy for Acurx Pharmaceuticals Inc.Trade Ideas & Intraday High Probability Setup Alerts - Newser
Can Acurx Pharmaceuticals Inc. rally from current levelsJuly 2025 Gainers & Weekly Sector Rotation Insights - Newser
Acurx Pharmaceuticals (NASDAQ:ACXP) Upgraded by Wall Street Zen to Hold Rating - Defense World
Multi asset correlation models including Acurx Pharmaceuticals Inc.Weekly Trade Report & Weekly Breakout Opportunity Watchlist - Newser
Does Acurx Pharmaceuticals Inc. fit your quant trading modelQuarterly Market Summary & Reliable Price Action Trade Plans - Newser
Tools to assess Acurx Pharmaceuticals Inc.’s risk profile2025 EndofYear Setup & Precise Swing Trade Alerts - Newser
Published on: 2025-08-16 01:02:27 - Newser
Intraday pattern recognizer results for Acurx Pharmaceuticals Inc.2025 Trade Ideas & Real-Time Stock Movement Alerts - Newser
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acurx Pharmaceuticals Inc Stock (ACXP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sailer Carl | Director |
Jan 06 '25 |
Buy |
1.01 |
24,631 |
25,000 |
137,183 |
| LUCI DAVID P | President and CEO |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,097,458 |
| Donohue James J. | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
22,352 |
| DELUCCIA ROBERT J | Director |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,010,196 |
| DEAN JACK H | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
21,776 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):